Damora Therapeutics, Inc. current report, 10 September 2024

Business Context and Reporting Period

This Form 8-K is filed by Galecto, Inc. (not Damora Therapeutics, Inc.) on September 10, 2024. The report details the completion of a one-time reverse stock split of the Company's common stock.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only quantitative data provided relates to share count:

  • Post-Split Shares Outstanding: 1,248,266 shares (as confirmed by Computershare, Inc. on September 10, 2024).
  • Reverse Stock Split Ratio: 1-for-25.

Material Changes

The primary material change is the effective implementation of the reverse stock split on August 29, 2024, at 5:00 p.m. Eastern Time. Every 25 shares of issued and outstanding common stock were automatically converted into one share. Fractional shares were rounded up to the nearest whole number.

Guidance, Outlook, and Risks

The filing contains no management guidance, financial outlook, risk factors, or discussion of contingencies. It is strictly a notification of the corporate action regarding the capital structure adjustment.

Investor Verification Checklist

  • Verify the ticker symbol GLTO on The Nasdaq Capital Market reflects the post-split share count.
  • Confirm the exact number of shares held in brokerage accounts has been adjusted by the 1-for-25 ratio.
  • Check for any fractional share rounding adjustments applied to individual holdings.
  • Note that the par value per share remains unchanged despite the split.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.